Warning! I reckon this FTSE 100 stock could fall off a cliff in 2019

Rupert Hargreaves thinks it’s only a matter of time before this high-flying FTSE 100 (INDEXFTSE: UKX) growth stock falls back to earth.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The best performing stock in the UK’s leading blue-chip index, the FTSE 100, last year was online retailer Ocado (LSE: OCDO). Shares in the company added more than 100% in 2018 and jumped 50% in a single day back in May when it revealed a tie-up with US supermarket Kroger.

However, over the past three months, the shares have slumped 9.5%, and while this is a slightly better performance than the rest of the FTSE 100, I think it could be a sign of things to come.

A sign of things to come

One of the reasons I’ve always been wary of the shares is their valuation, which has never been particularly appealing to me.

Should you invest £1,000 in Poolbeg Pharma Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Poolbeg Pharma Plc made the list?

See the 6 stocks

City analysts are not expecting the company to report a profit for 2018 or 2019, so it is difficult to figure out how much the shares should be worth on earnings alone, although we can use historical figures. 

In 2017 the company reported a profit of 0.4p per share implying the shares are currently trading at a historical P/E multiple of 2,025.

That being said, shares in Ocado have always been priced based on potential rather than actual earnings, which, as we have seen over the past 12 months, can result in significant gains when the company gets it right. But even Ocado itself has admitted that it will be some time before it realises profits from the significant deals struck with clients.

With this being the case, I think in the current market environment it could only be a matter of time before the shares crash back to earth. The market has been willing to give the business the benefit of the doubt over the past few years, but now volatility has returned, I believe investors will turn their backs on speculative stocks like this and instead put their money to work in defensive dividend-paying champions. 

I may be wrong, but this is what has happened in previous bear markets. If this trend plays out in 2019, then shares in Ocado could fall off a cliff.

Several disappointments 

Another speculative stock I’m avoiding in 2019 is Vectura (LSE: VEC). I used to be a fan of this business but ran out of patience following a series of disappointing trading updates.

After merging with peer Skyepharma several years ago, Vectura has struggled to find its groove. Following the merger, losses ballooned from £5.9m in 2012 to £86m in 2017, although cash generation has remained strong, which has enabled the company to push ahead in developing its treatment pipeline.

Today, management has informed the market that its efforts to restructure the business over the past few years are starting to pay off. According to the update, the group now expects “revenue to be in line with, and EBITDA to be materially above, current market consensus expectations.” This is undoubtedly great news, but there is still a sizeable speculative element here. 

The company’s future rests on the approval of a generic version of GlaxoSmithKline‘s blockbuster Advair Diskus, which it is in the process of developing with partner Hikma. Regulators have already turned down the first attempt to get this new product to market, and the partners face an uphill struggle to get it there. 

With the shares changing hands at 17.5 times forward earnings, I think Vectura is overvalued considering its uncertain outlook.

Pound coins for sale — 31 pence?

This seems ridiculous, but we almost never see shares looking this cheap. Yet this Share Advisor pick has a price/book ratio of 0.31. In plain English, this means that investors effectively get in on a business that holds £1 of assets for every 31p they invest!

Of course, this is the stock market where money is always at risk — these valuations can change and there are no guarantees. But some risks are a LOT more interesting than others, and at The Motley Fool we believe this company is amongst them.

What’s more, it currently boasts a stellar dividend yield of around 10%, and right now it’s possible for investors to jump aboard at near-historic lows. Want to get the name for yourself?

See the full investment case

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Man hanging in the balance over a log at seaside in Scotland
Investing Articles

Meta stock surges after bumper earnings. Should I buy now?

Jon Smith talks through the results just out that are sending Meta stock higher, along with why this could spark…

Read more »

Bronze bull and bear figurines
Investing Articles

Is the stock market now heading for a bull run?

This writer explains why he tries to look for signals rather than noise in the stock market when it comes…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

2 mega-cheap penny stocks to consider in May

These penny stocks look dirt cheap, reckons our writer Royston Wild. Here's why they could be great UK shares to…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

‘Sell in May’ – or buy bargain UK shares?

Christopher Ruane has no plans to take a blanket approach of selling in May and going away. He's hunting for…

Read more »

a couple embrace in front of their new home
Investing Articles

As the Persimmon share price barely moves on positive trading, is the market missing a chance?

How much longer will the Persimmon share price remain depressed? This latest update suggests things are looking up this year.

Read more »

Young black woman walking in Central London for shopping
Investing Articles

2 dividend stocks I’m staying well away from… for now

Dividend stocks can be a great source of long-term passive income, but investors shouldn’t ignore obvious risks when looking for…

Read more »

Front view of aircraft in flight.
Investing Articles

Why the IAG share price probably isn’t as cheap as it looks

The IAG share price looks like a bargain at the moment. But with this stock, there are some risks investors…

Read more »

Investing Articles

Forecast: in 12 months the red-hot NatWest share price could turn £10k into…

Last year the NatWest share price suddenly went off like a rocket. Harvey Jones examines whether the FTSE 100 bank…

Read more »